Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with
the addition of Avastin as 1st line treatment of colorectal cancer.